CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
New investors in 2023 must understand the current market landscape. Familiarize yourself with essential tips and strategies to thrive in investing.
28,151 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Could XRP slip below $2 by 2027? This guide breaks down the three big hurdles, explains why a lower price is plausibl...
As a new Fed chair, chair kevin warsh will confront two high-stakes tests in just 100 days. One test centers on polit...
Numbers matter, but stories move markets. This guide explains why narratives matter for stock prices and how investor...
A voluntary recall of thousands of Waymo AVs grabbed headlines, but the bigger story is the decade ahead for autonomo...
Moderna surged on pandemic-era demand. But what comes next? This piece examines why some investors are wary, what a t...
Cathie Wood of Ark Invest has sparked big talk about where crypto could go. This article outlines a practical approac...
Coinbase expands its crypto-backed loan service to include XRP and ADA, broadening access to liquidity without sellin...
Bitcoin is notoriously volatile, but history shows recurring recovery patterns after big crashes. This article explai...
A fresh AI-driven marketing platform launches a Reg A+ offering at $0.85 per share, claiming strong ROI through AI-po...
MP Materials has grabbed attention near the $60 level after high-profile partnerships. This guide breaks down whether...
Apple isn’t just a phone company. This article breaks down how many markets does Apple dominate—from devices to servi...